Huberman Lab releases a full episode on psilocybin's mechanisms, therapeutic evidence, and risks

Andrew Huberman, a neuroscientist at Stanford School of Medicine, devoted a full episode of his Huberman Lab podcast to psilocybin on 8 May 2023. The episode is one of the most widely distributed mainstream explanations of psilocybin pharmacology and is frequently cited by people encountering the topic for the first time.

What the episode covers

• What psilocybin is chemically, and how psilocin acts at serotonin 5-HT_2A receptors to trigger neuroplasticity.
• Clinical trial evidence for psilocybin in depression, addiction and other psychiatric conditions.
• The typical duration and phases of a psilocybin session, the dose categories commonly used, and the importance of set, setting and support.
• Which groups face elevated risk, including people with a personal or family history of psychosis, and the changing legal and medical landscape.

Why it matters

Popular science media shapes how the public understands psychedelic risk. The episode's emphasis on contraindications and on supervised settings mirrors the harm-reduction guidance in WikiPsilocybin's article Are magic mushrooms dangerous?. As with any podcast, listeners should treat dosing discussion as educational rather than as a protocol, and check specific claims against the primary literature.

← Back to recent events · Main article